...
首页> 外文期刊>International heart journal >Successful conversion from thiazide to tolvaptan in a patient with stage d heart failure and chronic kidney disease before heart transplantation.
【24h】

Successful conversion from thiazide to tolvaptan in a patient with stage d heart failure and chronic kidney disease before heart transplantation.

机译:患有d心力衰竭和慢性肾脏疾病的患者,在心脏移植前已成功从噻嗪类转化为托伐普坦。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Chronic kidney disease (CKD) is often complicated with advanced heart failure because of not only renal congestion and decreased renal perfusion but also prolonged use of diuretics at higher doses, which sometimes results in hyponatremia. Preoperative CKD is known to be associated with poor prognosis after heart transplantation (HTx). We experienced a stage D heart failure patient with CKD and hyponatremia who was switched from trichlormethiazide to tolvaptan. His hyponatremia was normalized, and his renal function was improved after conversion to tolvaptan. In patients with stage D heart failure, it may be useful to administer tolvaptan with a concomitant reduction in the dose of diuretics in order to preserve renal function and avoid hyponatremia before HTx.
机译:慢性肾脏病(CKD)通常并发晚期心力衰竭,这不仅是由于肾脏充血和肾脏灌注减少,而且长期使用高剂量利尿剂会导致低钠血症。已知术前CKD与心脏移植(HTx)后预后不良有关。我们经历了患有CKD和低钠血症的D期心力衰竭患者,该患者从三氯甲叠氮改为托伐普坦。转换为托伐普坦后,他的低钠血症恢复正常,肾脏功能得到改善。对于患有D期心力衰竭的患者,给予托伐普坦并同时减少利尿剂的剂量可能是有用的,以保持肾脏功能并避免HTx之前的低钠血症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号